HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
Sample Articles
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
PRODUCTS
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1638
The FDA has issued an Emergency Use Authorization (EUA) for a lower-strength (10 mcg/0.2 mL) formulation of the mRNA-based COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) for use in children 5-11 years old. The original formulation of (Comirnaty) (30 mcg/0.3 mL) is FDA-licensed for use in persons ≥16 years old and available under an EUA for use in adolescents 12-15 years...  read more...
More from issue 1638
Advance Release
Coming Soon
Antiviral Drugs for Influenza for 2021-2022
Drugs for Alcohol Use Disorder
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
Bupivacaine/meloxicam (Zynrelef) for Pain
Recommend to Your Library  
Previous Issues
© 2021 The Medical Letter, Inc.